CNX Therap buys Clinigen brands to expand hospital-injectable portfolio

11 August 2023

UK-based specialty pharmaceutical company CNX Therapeutics today announced it has successfully completed the acquisition of four cancer support products from Clinigen, a global pharmaceutical services company.

CNX Therapeutics, previously known as Sunovion, has acquired four medicines; Cardioxane (dexrazoxane), Savene (dexrazoxane), Totect (dexrazoxane) and Ethyol (amifostine), all of which help mitigate the side effects patients may experience when treated with other cancer therapies. Financial terms of the transaction were not disclosed.

The acquisition of these products represents a significant addition to CNX Therapeutics’ diverse portfolio of critical hospital products. The well-established products are marketed in more than 40 countries which brings expansion to CNX Therapeutics’ global portfolio, complementing its market presence across Europe and bringing new opportunities in Asia, Latin America, North America, Africa and the Middle East.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK